Hey, Tim Plaehn here.
Bitcoin just dipped.
Everyone's watching the price. But they're missing the real opportunity.
This could be the best buying moment we'll see all year.
I'm not talking about buying Bitcoin itself…
I've found a simple way to turn this moment into weekly income without buying crypto, opening a Coinbase account, or trading options.
Just a $45 investment you could find in your brokerage account right now.
And you could set yourself up for your first payout as soon as next Thursday.
After that? Every Thursday. Like clockwork.
We're talking potential payouts of $1,200 a month or more.
Click here to watch my Bitcoin Income Briefing.
I'll show you exactly how it works and why you need to act now to catch next week's payout.
Talk soon,
Tim Plaehn
Chief Income Strategist, Investors Alley
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
Written by Chris Markoch. Article Posted: 2/5/2026.
Quick Look
- Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after it delivered a double beat in its fourth-quarter earnings report.
Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer reported adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 drug candidate.
The Silver Strategy Hiding Inside IRAs (Ad)
In 2000, I told Barron's that a popular dot-com stock was headed for trouble. It dropped 90%. Now I'm making the opposite call on that same company: buy it now. This stock has become the lifeblood of AI data centers, yet almost no one has caught the story. While the media focuses on AI chip wars, they've missed this company's essential role in building out data centers. Their hardware is so critical that a single building uses enough of it to stretch around the world eight times. If you own Nvidia, you might want to pivot. If you missed Nvidia, this is your second chance at the AI data center buildout happening worldwide.
See the under-the-radar play fueling AI data centersPFE stock closed up about 4% on Feb. 4 as analysts and investors digested the report.
The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That starts with the company's push into obesity, where it reported a notable clinical update alongside the quarter.
Pfizer Wants a Piece of the Weight-Loss Drug Pie
The weight-loss drug market is expanding rapidly. Data shows the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035.
That's a compound annual growth rate (CAGR) of 9.7% and explains why billions of dollars are pouring into the industry as companies try to carve out market share.
For Pfizer, that opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks.
Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks.
The Growth Driver Investors May Be Missing
Immediately after the report, conventional wisdom pointed to the positive clinical trial results as the reason for the stock's gain. That may be true, but investors should note that effect could be temporary.
While Pfizer's GLP-1 shows promise, it will take time for sales to meaningfully impact the company's financials. Meanwhile, the GLP-1 space is expanding quickly, and as recent results from Eli Lilly & Co. (NYSE: LLY) make clear, the largest players aren't ceding leadership in obesity easily.
However, there are other reasons to be bullish on PFE — notably its oncology portfolio. Data from Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, and it is projected to climb to $648.08 billion by 2035, reflecting a CAGR of about 10.3%.
A Growing Pipeline Gives Pfizer Many Shots on Goal
As of late 2025, Pfizer has roughly 60 candidates in its product portfolio — translating to many opportunities to capture market share. The portfolio was strengthened significantly by its acquisition of Seagen in 2023.
Today, Pfizer's pipeline includes late-stage candidates such as Vepdegestrant — a next-generation targeted protein degrader (PROTAC) — paired with atirmociclib, a selective CDK4 inhibitor, to address ER+/HER2- metastatic breast cancer in later-stage trials.
Pfizer has other late-stage candidates as well, including:
- Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, which targets bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) that combines with Padcev to treat urothelial cancer — positioning these programs as potential blockbusters amid oncology growth.
But as noted earlier, Pfizer could bring multiple drugs to market in the next five to 10 years. That story improves further with the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector.
Pfizer integrates AI across R&D via partnerships with Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. The company says these tools can speed target identification by at least 50% with platforms like OncoScout. Internally, platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing.
These efforts played a role in the company's rapid development of Paxlovid and support catalysts planned for 2026 in both oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains.
Industry-wide, AI is projected to boost productivity 35% to 45% by improving preclinical decisions and trial design, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself near the forefront of AI adoption in drug discovery, which could be a meaningful benefit for investors over the medium and long term.
This email is a sponsored message provided by Investors Alley, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need assistance with your subscription, please feel free to email our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. U.S.A..
0 Response to "Bitcoin is down but your income is about to explode"
Post a Comment